SMAD2 and atrial fibrillation: In an experimental study, ARNI was validated to inhibit the p-Smad2/3, p-p38 MAPK, and p-JNK pathways, improve atrial tissue fibrosis, and reduce susceptibility to AF (36, 37) (Figure 4).